Last reviewed · How we verify

Rexulti — Competitive Intelligence Brief

Rexulti (BREXPIPRAZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical Antipsychotic [EPC]. Area: Neuroscience.

marketed Atypical Antipsychotic [EPC] D(2) dopamine receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Rexulti (BREXPIPRAZOLE) — Otsuka.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rexulti TARGET BREXPIPRAZOLE Otsuka marketed Atypical Antipsychotic [EPC] D(2) dopamine receptor 2015-01-01
Pramipexole (Mirapex) Pramipexole (Mirapex) Massachusetts General Hospital marketed Dopamine agonist D2 dopamine receptor, D3 dopamine receptor
Aripiprazole Augmentation Aripiprazole Augmentation Centre for Addiction and Mental Health marketed Atypical antipsychotic / dopamine partial agonist D2 dopamine receptor, 5-HT1A serotonin receptor
Adjunctive asenapine Adjunctive asenapine Lori Davis, MD marketed Atypical antipsychotic D2 dopamine receptor, 5-HT2A serotonin receptor
Quetiapine and Topiramate Quetiapine and Topiramate University of Cincinnati marketed Atypical antipsychotic + anticonvulsant mood stabilizer combination D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
LYBALVI LYBALVI Alkermes, Inc. marketed Atypical antipsychotic with opioid antagonist D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor
Asenapine - Double Blind Asenapine - Double Blind Organon and Co phase 3 Atypical antipsychotic D2 dopamine receptor, 5-HT2A serotonin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical Antipsychotic [EPC] class)

  1. · 2 drugs in this class
  2. AbbVie · 1 drug in this class
  3. Alkermes Inc · 1 drug in this class
  4. Eli Lilly · 1 drug in this class
  5. Hisamitsu · 1 drug in this class
  6. Intra-Cellular · 1 drug in this class
  7. Jazz Pharmaceuticals · 1 drug in this class
  8. Johnson & Johnson (Janssen) · 1 drug in this class
  9. Otsuka · 1 drug in this class
  10. Vanda Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rexulti — Competitive Intelligence Brief. https://druglandscape.com/ci/brexpiprazole. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: